Get started
Author

Laura McBride

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
2008 · Paul Richardson, Constantine Mitsiades, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 190
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
2012 · Paul G. Richardson, David Siegel, et al. · Blood · 162
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.
2009 · Paul Richardson, David Siegel, et al. · Blood · 39
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
2015 · David H. Vesole, Elizabeth Bilotti, et al. · British Journal of Haematology · 36
Dextromethorphan ameliorates effects of neonatal hypoxia on brain morphology and seizure threshold in rats
1997 · Nirupama Laroia, Laura McBride, et al. · Developmental Brain Research · 28
PDF
Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.
2007 · Paul G. Richardson, Constantine S. Mitsiades, et al. · Blood · 18
The Anion Gap and Routine Serum Protein Measurements in Monoclonal Gammopathies
2011 · Karen H. van Hoeven, Rosy E. Joseph, et al. · Clinical Journal of the American Society of Nephrology · 16
Inaccuracies in 24-Hour Urine Testing for Monoclonal Gammopathies
2009 · David S. Siegel, Laura McBride, et al. · Laboratory Medicine · 14
PDF
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series
2017 · David H. Vesole, Joshua Richter, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens
2016 · Larysa Sanchez, David H. Vesole, et al. · British Journal of Haematology · 12
PDF
Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,
2011 · Joshua R. Richter, Elizabeth Bilotti, et al. · Blood · 12
Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
2010 · David Samuel diCapua Siegel, Laura McBride, et al. · Blood · 10
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma
2021 · Noa Biran, Elli Gourna Paleoudis, et al. · American Journal of Hematology · 9
PDF
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma
2017 · Noa Biran, Tracy Andrews, et al. · Blood · 8
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
2010 · Paul G Richardson, David Siegel, et al. · Blood · 7
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma
2016 · Elizabeth Bilotti, David H. Vesole, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma
2019 · Meena Bansal, David S. Siegel, et al. · Blood · 5
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
2014 · David H. Vesole, David Samuel DiCapua Siegel, et al. · Journal of Clinical Oncology · 4
Real-world outcomes with panobinostat in patients with penta- and quad-refractory multiple myeloma.
2017 · Noa Biran, David H. Vesole, et al. · Journal of Clinical Oncology · 2
Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
2012 · Madiha Tufail, David S. Siegel, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial
2015 · Larysa Sanchez, Yucai Wang, et al. · Blood · 1
MM-102: Outcomes of Panobinostat with Proteasome Inhibitor or Immunomodulator-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Experience
2020 · Camille Johnson, Jun Chih Wang, et al. · Clinical Lymphoma Myeloma & Leukemia
Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
2016 · Noa Biran, David H. Vesole, et al. · Blood
bortezomib with refractory multiple myeloma who have received lenalidomide and Phase 1 study of pomalidomide MTD, safety, and efficacy in patients
2013 · Min Chen, M. Zaki, et al.
Managing Adverse Events in the Late-line Setting for Multiple Myeloma
2012 · Laura McBride, Ocn, et al.
Works count: 27
Citation count: 593
H-index: 11
I10-index: 12
Year
Topic
Type